• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Monogram Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    7/12/24 4:21:43 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email
    false --12-31 0001769759 0001769759 2024-07-09 2024-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): July 9, 2024

     

    Monogram Technologies Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41707   81-3777260
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification Number)

     

    3919 Todd Lane, Austin, TX 78744

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (512) 399-2656

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common Stock, par value $0.001 per share   MGRM   The Nasdaq Stock Market

      

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    ITEM 1.01ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

     

    Selling Agency Agreement

     

    On July 9, 2024, Monogram Technologies Inc. (“the Company”), entered into a selling agency agreement (the “Selling Agency Agreement”) with Digital Offering LLC (the “Digital Offering”), in connection with the Company’s best efforts offering (the “Offering”) of up to 4,444,445 units, with each unit consisting of (a)  one share of our 8.00% Series D Convertible Cumulative Preferred Stock (the “Series D Preferred Stock”) and (b) one common stock purchase warrant to purchase one share of our common stock, $0.001 par value per share (the “Common Stock”), for a total of 4,444,445 shares of our Series D Preferred Stock and warrants to purchase up to an aggregate of 4,444,445 shares of our Common Stock (and shares of Common Stock underlying shares of Series D Preferred Stock, PIK dividends on Series D Preferred Stock, and all such warrants).

     

    Digital Offering will act as the lead selling agent for the Offering pursuant to the terms of the Selling Agency Agreement. Under the Selling Agency Agreement, the Company has agreed to pay Digital Offering a commission of 5.8% of the gross proceeds received in the Offering, which shall be allocated by Digital Offering to members of its selling group and soliciting dealers in Digital Offering's sole discretion. The Company will reimburse Digital Offering for its reasonable and documented legal costs up to a maximum of $75,000, of which $25,000 has been paid to date.

     

    Digital Offering is acting on a “reasonable best efforts” basis, in connection with the Offering. Digital Offering is under no obligation to purchase any of the units or arrange for the sale of any specific number or dollar amount of shares of the units.

     

    Any securities sold under the Selling Agency Agreement will be issued pursuant to a prospectus supplement relating to the Offering dated July 9, 2024, and an accompanying base prospectus that form a part of the registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission (“SEC”) on June 4, 2024 (File No. 333-279927) and was declared effective on June 14, 2024 (collectively, the “Registration Statement”).

     

    The provisions of the Selling Agency Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreement and are not intended as a document for investors and the public to obtain factual information about the current state of affairs of the parties to that document. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the SEC.

     

    Subscription Agreement

     

    In connection with the Offering, the Company will enter into a Subscription Agreement (the “Subscription Agreement”), pursuant to which the Company agrees to sell to certain investors up to 4,444,445 units consisting of one share of Series D Preferred Stock and one Common Stock Purchase Warrant. Each investor must complete a Subscription Agreement and submit the applicable Subscription Price as set forth therein.

     

    Common Stock Purchase Warrant

     

    In connection with the Offering, the Company will issue to each investor a Common Stock Purchase Warrant. Each Common Stock Purchase Warrant is exercisable at any time beginning after 180 days from July 9, 2024 through and including July 8, 2024, unless earlier redeemed. Each Common Stock Purchase Warrant is exercisable to purchase one share of Common Stock at an exercise price at an exercise price of $3.375 per share, which is a 150% premium over the unit price of the securities offered in this Offering.

     

    The warrants will be issued in book-entry form pursuant to a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC as warrant agent, or the Warrant Agent. The warrants sold to the public will not be listed on any exchange or trading medium.

     

    2

     

     

    The foregoing descriptions of the Selling Agency Agreement, Form of Subscription Agreement, Form of Common Stock Purchase Warrant, and Form of Warrant Agency Agreement, are not complete and are qualified in their entirety by reference to the full text of each, copies of which are filed herewith as Exhibit 1.1, Exhibit 10.1, Exhibit 4.1, and Exhibit 4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    The legal opinion of Duane Morris LLP relating to the securities that may be offered and sold pursuant to the Registration Statement and the Selling Agency Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

     

    ITEM 5.03AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR

     

    On March 12, 2024, and subsequently further supplemented and ratified on July 12, 2024, in connection with the Offering, the Company Board adopted a Certificate of Designations to be filed with the Secretary of State of the State of Delaware (the “DE Secretary”) to create, out of the Company’s authorized but unissued preferred stock, the Series D Preferred Stock (the “Certificates of Designations”). On July 12, 2024, the Certificate of Designations was filed with the DE Secretary.

     

    Series D Preferred Stock

     

    The Series D Preferred Stock, par value $0.001 per share, shall be perpetual, subject to certain provisions in the Certificates of Designations, and the authorized number of shares of the Series D Preferred Stock shall by 6,000,000 shares. The number of shares of Series D Preferred Stock may be increased from time to time pursuant to the Certificate of Designations and any such additional shares of Series D Preferred Stock shall form a single series with the Series D Preferred Stock. Each share of Series D Preferred Stock shall have the same designations, rights, preferences, powers, restrictions and limitations as every other share of Series D Preferred Stock. The Series D Preferred Stock ranks, as to dividend rights and rights upon the Company’s liquidation, dissolution, or winding up, senior to all classes or series of the Company’s Common Stock.

     

    The foregoing description of the Series D Preferred Stock is subject to and qualified by reference to the full text of the Certificate of Designations, which is attached to this Current Report on Form 8-K as Exhibit 3.1.

     

    Cautionary Statement Regarding Forward-Looking Statements

     

    Statement contained in this Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the Prospectus Supplement and the Company's other filings with the SEC, including, but not limited to its annual filing on Form 10-K filed with the SEC on March 15, 2024, the Registration Statement, and any additional or final prospectus supplement to be filed with the SEC in connection with the Offering. The Company undertakes no duty to update any forward-looking statement made herein.

     

    3

     

     

    ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS

     

    (d)Exhibits:

     

    Exhibit No.   Description
    1.1   Selling Agency Agreement, dated July 9, 2024, between Digital Offering LLC and Monogram Technologies Inc.
    3.1   Certificate of Designations of Preferences, Rights and Limitations of 8.00% Series D Convertible Cumulative Preferred Stock
    4.1   Form of Common Stock Purchase Warrant
    4.2   Form of Warrant Agency Agreement
    5.1   Opinion of Duane Morris LLP
    10.1   Form of Subscription Agreement
    23.1   Consent of Duane Morris LLP (included in Exhibit 5.1)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

     

    4

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Monogram Technologies Inc.
       
    Dated: July 12, 2024 /s/ Benjamin Sexson
      Benjamin Sexson
      Chief Executive Officer

     

    5

     

    Get the next $MGRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Gray Colleen

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:59:13 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Gray Colleen

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:58:09 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Gray Colleen

    3 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:57:01 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    SEC Filings

    View All

    SEC Form EFFECT filed by Monogram Technologies Inc.

    EFFECT - Monogram Technologies Inc. (0001769759) (Filer)

    11/20/25 12:15:11 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Monogram Technologies Inc.

    EFFECT - Monogram Technologies Inc. (0001769759) (Filer)

    11/20/25 12:15:14 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12G filed by Monogram Technologies Inc.

    15-12G - Monogram Technologies Inc. (0001769759) (Filer)

    10/21/25 11:59:09 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Monogram Technologies with a new price target

    ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

    12/9/24 7:59:36 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

    The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee replacement procedure on a live patient. The procedure was performed at the Krishna Shalby Hospital in Ahmedabad India, as part of Monogram's multi-center clin

    7/29/25 9:30:05 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation o

    7/22/25 9:15:00 AM ET
    $AGEN
    $CLOV
    $MGRM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Medical/Dental Instruments

    $MGRM
    Leadership Updates

    Live Leadership Updates

    View All

    Monogram Accepted to NVIDIA Inception Program

    Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

    4/11/24 1:20:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Reports First Quarter 2025 Financial Results

    Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

    5/14/25 4:01:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

    AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

    11/12/24 8:31:00 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care